Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation of new long-term and real-world evidence for its leading cardiovascular therapy, Camzyos® (mavacamten), at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. The data reinforce the medicine’s role as a transformative, disease-modifying treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)—a chronic and often debilitating condition that affects the heart’s ability to pump blood effectively.
Science Significance
Bristol Myers Squibb’s latest findings build on a growing foundation of evidence confirming Camzyos’ durable efficacy and safety. Results from the EXPLORER-LTE cohort of the MAVA Long-Term Extension study, now approaching four years of follow-up, demonstrated sustained improvement in cardiac obstruction, heart structure, and biomarker levels. These outcomes validate Camzyos as a first-in-class therapy that targets the underlying mechanism of hypertrophic cardiomyopathy, rather than merely alleviating symptoms. Complementary real-world studies, including COLLIGO-HCM, MARVEL-HCM, COMPASS-HCM, and the U.S. REMS program, confirmed consistent clinical benefits across diverse populations. No new safety concerns were observed, reinforcing Camzyos’ strong benefit–risk profile in daily practice.
Regulatory Significance
As the first and only approved cardiac myosin inhibitor, Camzyos has redefined regulatory pathways in cardiology. It is now approved in more than 50 countries and regions, spanning five continents. The growing pool of long-term and real-world data is expected to support regulatory expansion into non-obstructive HCM (nHCM) and potential label updates worldwide. Meanwhile, milvexian, developed under the BMS–Johnson & Johnson collaboration, is advancing through Phase 3 Librexia trials—the most comprehensive global program for a Factor XIa inhibitor. These studies aim to deliver the next generation of anticoagulants that prevent thrombosis with a lower bleeding risk, aligning with global regulatory priorities for safer cardiovascular interventions.
Business Significance
Advertisement
The AHA 2025 data affirm BMS’s leadership in cardiovascular therapeutics and strengthen its commercial positioning. Camzyos has become a global standard of care for NYHA class II–III oHCM, with more than 20,000 U.S. patients treated and over 4,000 prescribers since launch. The long-term data further support durable demand, sustained efficacy, and differentiation from traditional therapies like beta-blockers or invasive septal reduction procedures. At the same time, milvexian’s progress represents a high-value pipeline opportunity, with blockbuster potential in the global anticoagulant market. The collaboration leverages BMS’s development expertise and Johnson & Johnson’s commercial infrastructure, positioning the alliance to capture a projected $10 billion market opportunity in the coming decade.
Patients’ Significance
For patients, these findings mark a turning point in the treatment of hypertrophic cardiomyopathy. Camzyos enables significant, sustained improvement in symptoms, quality of life, and exercise capacity, while reducing hospital and emergency room visits. Its selective, reversible cardiac myosin inhibition restores normal cardiac physiology, offering patients a non-surgical, disease-modifying option. With broader global availability and integration into clinical guidelines, Camzyos is improving outcomes for tens of thousands of individuals worldwide who previously had limited therapeutic choices.
Policy Significance
The CAMZYOS REMS program serves as a benchmark for balancing innovation with patient safety oversight. The program’s structured monitoring—requiring certified prescribers, echocardiographic tracking, and pharmacy controls—ensures safe use while maintaining access to advanced therapies. This approach may inform future regulatory frameworks for high-impact precision medicines. Furthermore, the growing body of real-world REMS data supports health system confidence and payer adoption, potentially influencing reimbursement models toward value-based cardiovascular care.
Transaction Highlights
At AHA 2025, Camzyos and milvexian jointly highlighted BMS’s dual commitment to structural heart disease and thrombosis management. The EXPLORER-LTE, COMPASS-HCM, COLLIGO-HCM, and MARVEL-HCM data deepen clinical credibility, while ODYSSEY-HCM’s late-breaking results expand the therapeutic frontier into non-obstructive disease. Milvexian’s Phase 3 Librexia program continues as a cornerstone of the BMS–J&J cardiovascular alliance, aimed at redefining anticoagulation with Factor XIa inhibition. Together, these efforts reinforce BMS’s strategic vision of delivering transformative therapies backed by real-world and regulatory evidence.
Source: Bristol Myers Squibb Press Release
